SLC22A12: Solute carrier family 22 member 12
Electroneutral antiporter that translocates urate across the apical membrane of proximal tubular cells in exchange for monovalent organic or inorganic anions.
- Drugs that act on it: 8
- Approved: 3
- In phases 1 to 3: 5
- Sponsors: 7
Who is on it, and how far along
Every drug ChEMBL records acting on SLC22A12, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 8
Approved3
Phase 32
Phase 23
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Ardea Biosciences, Inc.113%
- Crystalys Therapeutics113%
- Gilead Sciences113%
- InventisBio Co., Ltd113%
- Ironwood Pharmaceuticals113%
- Jiangsu Hengrui Medicine113%
- Novartis Pharmaceuticals113%
| BenzbromaroneWithdrawn | Approved | InventisBio Co., Ltd | Small molecule | Inhibitor | 1 |
| LesinuradBoxed warning | Approved | Ironwood Pharmaceuticals | Small molecule | Inhibitor | 0 |
| Sulfinpyrazone | Approved | Novartis Pharmaceuticals | Small molecule | Inhibitor | 0 |
| Dotinurad | Phase 3 | Crystalys Therapeutics | Small molecule | Inhibitor | 5 |
| SHR-4640 | Phase 3 | Jiangsu Hengrui Medicine | Small molecule | Inhibitor | 1 |
| Arhalofenate | Phase 2 | Gilead Sciences | Small molecule | Inhibitor | 0 |
| Pratosartan | Phase 2 | — | Small molecule | Inhibitor | 0 |
| Verinurad | Phase 2 | Ardea Biosciences, Inc. | Small molecule | Inhibitor | 0 |
- Gout0.80
- Hyperuricemia0.70
- Hereditary renal hypouricemia0.66
- Hypouricemia, renal0.47
- Obesity disorder0.44
- Acquired metabolic disease0.37
- Overnutrition0.35
- Obstructive sleep apnea syndrome0.28
- Hypertensive disorder0.27
- Placenta praevia0.22
- Type 2 diabetes mellitus0.22
- Hereditary disease0.19
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL6120, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q96S37, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets